Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | FABP3 | P05413 | 1/20 | 0.42 |
| ▸ | FABP4 | P15090 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27205400 | 0.86 | PSIP1 (0.57) | CYP3A4PSIP1SMN1; SMN2GAAMAPT | |
| SCHEMBL27177326 | 0.86 | PSIP1 (0.57) | CYP3A4PSIP1SMN1; SMN2GAAMAPT | |
| SCHEMBL29985876 | 0.86 | PSIP1 (0.57) | CYP3A4PSIP1SMN1; SMN2GAAMAPT | |
| SCHEMBL30887308 | 0.86 | PSIP1 (0.57) | CYP3A4PSIP1SMN1; SMN2GAAMAPT | |
| SCHEMBL10271608 | 0.84 | CYP3A4 (0.53) | CYP3A4PSIP1GAAMAPTLMNA | |
| SCHEMBL1699506 | 0.83 | CYP3A4 (0.52) | CYP3A4PSIP1GAAMAPTFABP3 | |
| SCHEMBL1699493 | 0.83 | CYP3A4 (0.52) | CYP3A4PSIP1GAAMAPTLMNA | |
| SCHEMBL1699278 | 0.82 | CYP3A4 (0.49) | CYP3A4PSIP1MAPTFABP3FABP4 | |
| SCHEMBL1699246 | 0.82 | CYP3A4 (0.49) | CYP3A4PSIP1MAPTFABP3FABP4 | |
| SCHEMBL12630033 | 0.81 | PSIP1 (0.60) | CYP3A4PSIP1SMN1; SMN2FABP3FABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220323494-A1 | Novel Control Switch | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220323494-A1 | Novel Control Switch | TNFRSF9, TNFRSF1A, TNFSF11 | CYP3A4 3831/4885PSIP1 1442/4885SMN1; SMN2 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.